pI: 8.5363 |
Length (AA): 3811 |
MW (Da): 417033 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 3
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1732 | 1969 | 5cwm (A) | 10 | 226 | 17.00 | 0 | 0.08 | 0.173351 | -0.64 |
1817 | 1934 | 5hmo (A) | 814 | 922 | 20.00 | 0.17 | 0.01 | 0.226563 | -0.86 |
3191 | 3273 | 4o9b (A) | 249 | 319 | 20.00 | 0 | 0.03 | 0.246679 | -2.26 |
3227 | 3323 | 5hmo (A) | 806 | 903 | 30.00 | 0.6 | 0 | 0.470753 | -1.88 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | VEG Tachyzoite, ME49 Bradyzoite. | Gregory Sibley/Greg |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | ME49 Tachyzoite, ME49 Oocyst. | Gregory Fritz HM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | ME49 merozoite. | Hehl AB |
Sibley/Greg | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Gregory | ToxoDB |
Ortholog group members (OG5_128307)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G67960 | protein POLLEN DEFECTIVE IN GUIDANCE 1 |
Babesia bovis | BBOV_II004690 | eukaryotic membrane protein, putative |
Brugia malayi | Bm1_50325 | FLJ90013 protein |
Candida albicans | CaO19.3658 | similar to S. cerevisiae YER140W |
Candida albicans | CaO19.11142 | similar to S. cerevisiae YER140W |
Caenorhabditis elegans | CELE_F26F2.7 | Protein F26F2.7 |
Cryptosporidium hominis | Chro.40200 | hypothetical protein |
Cryptosporidium parvum | cgd4_1760 | hypothetical protein with 2 transmembrane domains |
Dictyostelium discoideum | DDB_G0277313 | DUF747 family protein |
Drosophila melanogaster | Dmel_CG7218 | CG7218 gene product from transcript CG7218-RB |
Echinococcus granulosus | EgrG_000890200 | enhancer of rudimentary |
Echinococcus granulosus | EgrG_000890100 | Membrane proteinTapt1 CMV receptor |
Entamoeba histolytica | EHI_100500 | hypothetical membrane-spanning protein |
Echinococcus multilocularis | EmuJ_000890100 | Membrane protein,Tapt1 CMV receptor |
Echinococcus multilocularis | EmuJ_000890200 | enhancer of rudimentary |
Echinococcus multilocularis | EmuJ_000011400 | Membrane protein,Tapt1 CMV receptor |
Homo sapiens | ENSG00000169762 | transmembrane anterior posterior transformation 1 |
Leishmania braziliensis | LbrM.07.0150 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_070310.1 | Eukaryotic membrane protein family, putative |
Leishmania infantum | LinJ.07.0310 | hypothetical protein, conserved |
Leishmania major | LmjF.07.0150 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.07.0150 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_01351 | hypothetical protein |
Mus musculus | ensembl-mmu:ENSMUSG00000046985 | transmembrane anterior posterior transformation 1 |
Neospora caninum | NCLIV_004580 | hypothetical protein |
Oryza sativa | 4333908 | Os03g0715400 |
Onchocerca volvulus | OVOC12856 |
|
Onchocerca volvulus | OVOC7062 |
|
Plasmodium berghei | PBANKA_1216600 | cyclic amine resistance locus protein, putative |
Plasmodium falciparum | PF3D7_0321900 | cyclic amine resistance locus protein |
Plasmodium knowlesi | PKNH_0818900 | cyclic amine resistance locus protein, putative |
Plasmodium vivax | PVX_095140 | cyclic amine resistance locus protein, putative |
Plasmodium yoelii | PY03667 | hypothetical protein |
Saccharomyces cerevisiae | YER140W | Emp65p |
Schistosoma japonicum | Sjp_0308130 | Enhancer of rudimentary homolog, putative |
Schistosoma mansoni | Smp_175200 | hypothetical protein |
Schmidtea mediterranea | mk4.001853.06 | Protein TAPT1 homolog |
Schmidtea mediterranea | mk4.000177.12 | Enhancer of rudimentary homolog |
Trypanosoma brucei gambiense | Tbg972.8.1430 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.8.1800 | Eukaryotic membrane protein family, putative |
Trypanosoma congolense | TcIL3000_8_1730 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.503565.20 | Eukaryotic membrane protein family, putative |
Trypanosoma cruzi | TcCLB.511393.40 | Eukaryotic membrane protein family, putative |
Toxoplasma gondii | TGME49_321340 | membrane protein, putative |
Theileria parva | TP02_0285 | hypothetical protein, conserved |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.1800 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.1800 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.1800 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.1800 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_F26F2.7 | Caenorhabditis elegans | embryonic lethal | wormbase |
PBANKA_1216600 | Plasmodium berghei | Essential | plasmo |
TGME49_321340 this record | Toxoplasma gondii | Essentiality uncertain | sidik |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.1